Despite the impressive results of autologous CAR-T cell therapy in refractory B
lymphoproliferative diseases, CAR-NK immunotherapy emerges as a safer, faster, and cost …

The tumor microenvironment consists of a multiplicity of cells such as cancer cells,
fibroblasts, endothelial cells, and immune cells within the specific parenchyma. It has been …

Ligation of the inhibitory receptor NKG2A by its ligand HLA-E negatively regulates the
activation of natural killer (NK) cells, as well as subsets of CD8+ T cells and innate T cell …

The first-in-class inhibitor of exportin-1 (XPO1) selinexor is currently under clinical
investigation in combination with the BTK inhibitor ibrutinib for patients with chronic …

Currently-available therapies for newly-diagnosed pediatric and adolescent patients with
Hodgkin lymphoma result in> 95% survival at 5 years. Long-term survivors may suffer from …

Multiple myeloma (MM), a stage-developed plasma cell malignancy, evolves from
monoclonal gammopathy of undetermined significance (MGUS) or smoldering MM (SMM) …

NK cells are promising cellular therapeutics against hematological and solid malignancies.
Immunogenetic studies have identified that various activating killer cell Ig-like receptors …

Multiple myeloma (MM) remains an incurable, genetically heterogeneous disease
characterized by the uncontrolled proliferation of transformed plasma cells nurtured within a …

Natural killer (NK) cells are cytotoxic innate lymphoid cells that participate in anti-tumour and
anti-viral immune responses. Their ability to rapidly destroy abnormal cells and to enhance …

XPO1 is an attractive and promising therapeutic target frequently overexpressed in multiple
hematological malignancies. The clinical use of XPO1 inhibitors in natural killer/T-cell …